Gain Therapeutics (NASDAQ:GANX) Stock Price Up 10.4% – Here’s Why

Gain Therapeutics, Inc. (NASDAQ:GANX) traded up 10.4% during mid-day trading on Wednesday . The company traded as high as $2.45 and last traded at $2.44. 255,189 shares traded hands during trading, an increase of 23% from the average session volume of 207,210 shares. The stock had previously closed at $2.21.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GANX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, November 25th. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $7.25.

Gain Therapeutics Stock Performance

The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The company has a market cap of $64.71 million, a PE ratio of -2.22 and a beta of 0.14. The firm has a fifty day simple moving average of $1.99 and a 200-day simple moving average of $1.78.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GANX. Sprott Inc. acquired a new position in Gain Therapeutics in the fourth quarter valued at $30,000. Benedict Financial Advisors Inc. acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth $35,000. Renaissance Technologies LLC grew its position in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Gain Therapeutics by 48.0% in the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after buying an additional 88,236 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.